名稱 | CCR4/Ga15/CHO |
型號(hào) | CBP71336 |
報(bào)價(jià) | ![]() |
特點(diǎn) | CCR4/Ga15/CHO 凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 降糖&減肥明星靶點(diǎn):GLP1R/GIPR/GCGR
- 老靶點(diǎn)迭代突破創(chuàng)新:Her2靶點(diǎn)細(xì)胞模型
- PD-1/PD-L1:研發(fā)過剩還是大有可為
- ERBB2基因檢測(cè)標(biāo)準(zhǔn)品
- 拯救偏頭痛!CGRP及其受體拮抗劑研究進(jìn)展
- 【連載-企業(yè)參考品】胃癌的診斷參考品的選擇
- 甲基丙二酸血癥(MMA)標(biāo)準(zhǔn)品上新
- 鑒別出促進(jìn)黑色素瘤進(jìn)展的關(guān)鍵蛋白,開發(fā)出新型癌癥靶向療法
- IL-21藥篩細(xì)胞模型
- 【產(chǎn)品推介】CD47&SIRPɑ 細(xì)胞篩選模型
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > GPCR細(xì)胞株 > CBP71336CCR4/Ga15/CHO

- 詳細(xì)內(nèi)容
CBP71336 | |
I. Background | |
C-C chemokine receptor type 4 is a protein that in humans is encoded by the CCR4 gene.The protein encoded by this gene belongs to the G protein-coupled receptor family. It is a receptor for the following CC chemokines:CCL2 (MCP-1) CCL4 (MIP-1) CCL5 (RANTES) CCL17 (TARC) CCL22 (Macrophage-derived chemokine). Chemokines are a group of small structurally related proteins that regulate cell trafficking of various types of leukocytes. The chemokines also play fundamental roles in the development, homeostasis, and function of the immune system, and they have effects on cells of the central nervous system as well as on endothelial cells involved in angiogenesis or angiostasis. | |
II. Introduction | |
Host Cell: | CHO |
Stability: | 20 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | F12K+10%FBS+100μg/ml Hygromycin B+200μg/ml G418 |
Mycoplasma Status: | Negative |
Storage: | Liquid nitrogen immediately upon delivery |
Application(s): | Functional assay for CCR4 receptor |
Transducer: | Gi |
Ⅲ. Description of Host Cell Line | |
Organism: | Hamster |
Tissue: | Ovary |
Morphology: | Epithelial |
Growth Properties: | Adherent |
Ⅳ. Representative Data | |
Figure 1. Dose Response of Recombinant Human CCL22 in CCR4/Gα15 CHO cells(C11). |